FDA Issues Warning About Compounded Versions of Wegovy, Ozempic
The FDA does not review compounded drugs for safety, effectiveness, or quality; compounded medications are not FDA-approved
Diagnosis & Disease Information
Get Moving: Prescribing Exercise to End Insulin Resistance
Afternoon high intensity exercise may have a greater effect on lowering blood glucose levels in patients with diabetes than morning high intensity interval training.
Substantial Weight Loss Reductions Observed With Tirzepatide in T2D Patients
Tirzepatide is a once-weekly, dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.
Sugar-Sweetened Beverage Intake Linked to Mortality, CVD in T2D
Increased hazard ratio noted for all-cause mortality, CVD incidence and mortality for higher sugar-sweetened beverage intake.
Macrovascular Complication Is Unaffected by Glucose Control Intensity in Diabetes
Researchers investigated the role of glucose control on multiple cardiovascular disease-related events in patients with type 2 diabetes.
Greater HbA1c, Weight Loss Reductions Seen With Oral Semaglutide at Higher Doses
Novo Nordisk plans to file for regulatory approval of the 25mg and 50mg dosage strengths in 2023.
Semaglutide and Tirzepatide: Top 5 Things Clinicians Should Know
Obesity experts discuss how semaglutide and tirzepatide are changing the treatment landscape and challenges affecting access including drug shortages, inappropriate prescribing, insurance coverage, and cost.
More than 60% of Adults With Type 1 Diabetes Have Overweight, Obesity
Those with type 1 diabetes are least likely to increase physical activity, reduce caloric intake to manage overweight or obesity.
SGLT2 Inhibitor Use in Case of Acute Decompensated Heart Failure With Edema
Case demonstrates initiation of a sodium-glucose cotransporter-2 (SGLT2) inhibitor in a patient with type 2 diabetes and heart failure.
We Have Better Obesity Medications, but Access Is Lagging
Obesity experts discuss the cost of newer obesity medications (eg, GLP-1 agonists) and access issues, including Ozempic shortages.
- Loading...
Loading...
Next post in Obesity Information Center
Loading... 
Loading...